New York, NY, United States of America

Kelvin Cooper


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 27(Granted Patents)


Location History:

  • New York, NY (US) (1991)
  • Groton, CT (US) (1994)
  • Nonak, CT (US) (1994)

Company Filing History:


Years Active: 1991-1994

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Kelvin Cooper

Introduction

Kelvin Cooper is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of analgesics. With a total of 3 patents to his name, Cooper's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Among his latest patents is the invention of Imidazopyridine PAF/H1 antagonists. This includes the compound 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide, which serves as an analgesic. His innovative method focuses on producing analgesia and treating anti-inflammatory diseases in human subjects while avoiding proteinuria. This is achieved by administering 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide or a pharmaceutically acceptable base salt thereof.

Career Highlights

Kelvin Cooper is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to further his research and development efforts in the pharmaceutical industry.

Collaborations

Cooper has collaborated with several talented individuals in his field, including David Alker and Robert J Bass. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Kelvin Cooper's innovative work in the pharmaceutical industry showcases his dedication to improving medical treatments. His patents reflect a commitment to addressing significant health challenges, and his collaborations further enhance the impact of his contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…